This is a non-material clinical update — no revenue, approval, or partnership data. Monitor the July 2026 conference presentation for efficacy/safety data, but historical stock reaction to similar milestones has been negative (T+20 avg -14.58%). No trading catalyst until actual data readout.
Price Chart
Executive Summary
Alpha Tau announced that an abstract on its Alpha DaRT combination therapy with pembrolizumab for elderly head and neck cancer patients was accepted for a podium presentation at the AHNS International Conference in July 2026. The filing is a routine clinical milestone update with no new financial data or regulatory approval, and the stock has historically not reacted positively to similar announcements.
Key Facts
- Abstract on Alpha DaRT + pembrolizumab in elderly HNSCC patients accepted for podium presentation at AHNS 12th International Conference (July 18-22, 2026, Boston).
- Presentation scheduled for July 21, 2026, during Proffered Papers session on Radiation and Adjuvant Therapies.
- Study conducted at Hadassah Medical Center, Jerusalem; complete top-line data to be presented.
- No financial figures, revenue, EPS, or guidance changes reported in the filing.
- Prior 20-F (filed March 9, 2026) noted 88,009,737 ordinary shares outstanding as of Dec 31, 2025.
Financial Impact
No financial impact disclosed; pre-revenue clinical-stage company.
Risk Factors
- Historical pattern shows negative stock reaction to similar clinical milestone announcements (avg T+20 -14.58%).
- No regulatory approval or commercial revenue; company remains pre-revenue with significant cash burn.
- Podium presentation acceptance does not guarantee positive clinical data or eventual regulatory approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-051929 |
| Document: ea0289093-6k_alphatau.htm | 0001213900-26-051929 |
| Document: 0001213900-26-051929-index-headers.html | 0001213900-26-051929 |
| Document: 0001213900-26-051929-index.html | 0001213900-26-051929 |
| Document: 0001213900-26-051929.txt | 0001213900-26-051929 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 17w ago | 6-K | $1.02 $4.00 | ▲ +292.16% | ▲ +289.66% | — |
Jun 1, 2026 17w ago | 6-K | $1.02 $3.89 | ▲ +281.37% | ▲ +280.14% | — |
May 18, 2026 19w ago | 6-K | $1.02 $3.89 | ▲ +281.37% | ▲ +275.08% | — |
May 11, 2026 20w ago | 6-K | $1.02 $3.37 | ▲ +230.39% | ▲ +226.00% | — |
May 11, 2026 20w ago | 6-K | $1.02 $3.37 | ▲ +230.39% | ▲ +226.00% | — |
May 8, 2026 21w ago | 6-K | $1.02 $3.30 | ▲ +223.53% | ▲ +218.69% | — |
May 8, 2026 21w ago | 6-K | $1.02 $3.30 | ▲ +223.53% | ▲ +218.69% | — |
May 7, 2026 21w ago | 6-K | $1.02 $2.58 | ▲ +152.94% | ▲ +149.11% | — |
May 5, 2026 21w ago | 6-K | $1.02 $2.70 | ▲ +164.71% | ▲ +161.97% | — |
May 4, 2026 21w ago | 6-K | $1.02 $2.29 | ▲ +124.51% | ▲ +122.65% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access